Regulatory/HTA interface under the HTA Regulation (HTAR)

9th Industry Standing Group (ISG) meeting, 28 June 2024

Presented by
Michael Berntgen, Head of Scientific Evidence Generation Department and
Joao Ferreira, HTAR implementation lead
Overview of implementation activities
European collaboration between regulators and HTA bodies

• Since 2010, EMA and the European Network for Health Technology Assessment (EUnetHTA) have been working closely on topics of mutual interest
  ➢ Cooperation was facilitated through coordination of HTA bodies in EU-financed Joint Actions, and a subsequent tender for service (EUnetHTA ceased to exist in mid-September 2023)

• The new HTA Regulation in Europe, applicable from January 2025, recognizes the value of such collaboration
  ➢ Current implementation period (see Towards a permanent collaboration framework for EMA and Health Technology Assessment bodies)

• The aim of this regulatory/HTA cooperation is to build synergies between regulatory evaluation and HTA along the medicine lifecycle
HTA Regulation – Key principles

• Joint work on common scientific, clinical aspects
• High-quality, timely scientific reports
• Better evidence-base, efficiency, non-duplication

• Joint work driven by Member States’ HTA bodies
• Ensure use in national HTA processes

• Improved transparency and inclusiveness

• Recognised value of regulatory/HTA collaboration along the medicines lifecycle to create synergies

• Stepwise implementation
Collaboration with EMA under the HTA Regulation*

Further details through Implementing Acts to be adopted by the EC (Art 15, 20)

Transversal elements in the Regulation to facilitate such work, supported by the European Commission, include the sharing of confidential information

Notes:
- "Joint" refers to collaborative work amongst HTA bodies
- Activities cover medicinal products and medical devices / IVDs

* Regulation (EU) 2021/2282, entered into force in Jan 2022 and applies as of Jan 2025
HTA Regulation
Implementation timeline

Adoption
December 2021

Entry into force
January 2022

Preparatory phase for implementation

Date of Application
January 2025

Joint Clinical Assessment Full Scope
January 2030

Application phase

• Setting up the Coordination Group (HTACG) and its subgroups (EC)
• Setting up the Stakeholder Network (EC)
• Developing the IT platform (EC)
• Drafting implementing and delegated acts (EC)

Joint Scientific Consultations (JSC)

+ Stepwise build-up of Joint Clinical Assessments (JCA) scope for medicines:
  - From Jan. 2025: cancer drugs, ATMPs (from date of application)
  - From Jan. 2028: orphan drugs (3 years after date of application)

• Drafting guidance documents (CG)

Service contract
EUnetHTA21

Workplan activities

Classified as public by the European Medicines Agency
Concluding EMA/EUnetHTA bilateral meeting on 14.09.2023
“Celebrating joint achievements - progressing future collaboration”
# Implementation rolling plan – Development of Implementing Acts (status June 2024)

<table>
<thead>
<tr>
<th>Implementing act for joint clinical assessments</th>
<th>HTAR Articles 15.1(a) and (c); 25.1(b); 26.1</th>
<th><strong>Commission Implementing Regulation (EU) 2024/1381</strong> of 23 May 2024 laying down, pursuant to Regulation (EU) 2021/2282 on health technology assessment, procedural rules for the interaction during, exchange of information on, and participation in, the preparation and update of joint clinical assessments of medicinal products for human use at Union level, as well as templates for those joint clinical assessments</th>
<th>Adopted 23 May 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adoption</td>
<td>Public consultation finished Under public consultation</td>
<td>HTAR Article 25.1(a)</td>
<td>Conflict of interest management Cooperation by exchange of information with the European Medicines Agency (EMA)</td>
</tr>
<tr>
<td>Adoption</td>
<td>HTAR Articles 15.1 (a) and (b); 20.1 (c) and (d)</td>
<td>HTAR Article 20.1</td>
<td>Joint Scientific Consultations for medicinal products</td>
</tr>
<tr>
<td>Adoption</td>
<td>HTAR Article 20.1</td>
<td>Joint Scientific Consultations for medical devices</td>
<td>by Q4 2024 Planned</td>
</tr>
<tr>
<td>Adoption</td>
<td>HTAR Articles 15.1 (b) and (c); 25.1(b); 26.1</td>
<td>Joint Clinical Assessments for medical devices</td>
<td>by Q4 2024 Planned</td>
</tr>
</tbody>
</table>
Operational aspects of the parallel processes for centralised procedure and joint clinical assessment
Concepts for the implementation of key processes: *Joint Clinical Assessment (JCA)* for human medicines

**Key principles:**

- Exchange with the [HTACG](#) secretariat during the CP assessment
- Exchanges at milestones – focused (relevant / necessary)
- Maintain the independence of Benefit/Risk assessment
- Administrative automation as much as possible

**Implementation status:**

- Identification of MA applications in JCA scope during pre-submission phase (from 06/2024)
- Development of operations under Article 3 of the Implementing Act on JCA-MP
Requirements in the Implementing Act on Joint Clinical Assessment (medicinal products)

Exchange of information with EMA (acc to Article 3)

• Notification of HTA secretariat about MAA / EoI submission in scope of JCA
• Information about positive validation and timelines
• During the assessment, information about changes to timelines and substantial questions / outstanding issues impacting the therapeutic indication
• Provision of CHMP Opinion (AR and SmPC)

As of 13 January 2025, all medicinal products falling under the scope of Article 7 of Regulation (EU) 2021/2282, for which the applicant declares in its application for marketing authorisation that it contains a new active substance and the therapeutic indication is the treatment of cancer and those that concern ATMPs are subject to JCA.

MAA – Marketing Authorisation Application; EoI = Extension of Indications; AR = Assessment Report; SmPC = Summary of Products Characteristics
Changes to the Letter of Intent (LoI)

General principle:
EMA and the secretariat of the Member State Coordination Group on HTA (HTACG) have agreed to use the same form (i.e. EMA LoI) for respective notifications.

Instructions to applicants:
Applicants should declare in the LoI whether their application falls under the scope of Article 7 of Regulation (EU) 2021/2282 and, therefore, is subject to JCA.

Information on the product:

EMA deliverables:
1. Update to LoI
2. Update to pre-authorisation guidance document (Q 2.4, 2.7, 2.10) and collapsible Q&As (EMA website)
Products in scope of JCA under the HTAR

**Implementation Timeline:** Three key milestones (in 2025, 2028 and 2030, respectively) with the dates referring to receipt of MAA submission by EMA

**13 January 2025**
Medicinal products with new active substances for **cancer** treatment
**Advanced Therapy**
Medicinal Products (ATMPs)

**14 January 2028**
**Orphan** medicinal products

**14 January 2030**
**All other** medicinal products under Article 7 of Regulation 2021/2282
Parallel EC/EMA communication on 21st June 2024

Pre-authorisation guidance

2.4.1.2 Declaring a product in scope of Joint Clinical Assessment (JCA) under the HTA Regulation (Regulation (EU) 2021/2282) in the Letter of Intent NEW June 2024

As of 13 January 2025, all medicinal products falling under the scope of Article 7 of Regulation (EU) 2021/2282, for which the applicant declares in its application for marketing authorisation that it contains a new active substance and the therapeutic indication is the treatment of cancer and those that concern ATMPs are subject to JCA. As of 14 January 2028, all medicinal products designated as orphan medicinal products and, as of 14 January 2030, all other medicinal products falling under the scope of Article 7 of Regulation (EU) 2021/2282 are also subject to JCA.

To facilitate and prepare the respective assessments, EMA and the secretariat of the Member State Coordination Group on HTA (HTACG) have agreed to use the same form for respective notifications. Therefore, on the basis of the type of submission for a marketing authorisation application and the planned submission time, applicants should declare in the Pre-submission request form whether their application falls under the scope of Article 7 of Regulation (EU) 2021/2282 and therefore is subject to JCA. This declaration shall be made alongside the request under section 1.1.1 (when selecting the indent "Intent to submit MA").

See Joint clinical assessment of medicinal products: Submission of early information by health technology developers - European Commission and Pre-authorisation guidance | European Medicines Agency

13 Regulatory/HTA Interface under the HTA Regulation (HTAR)
For more information on HTAR implementation, see [here](#).

**Implementation of the Regulation on health technology assessment**

The [Regulation (EU) 2021/2282 on health technology assessment](#) (HTAR) entered into force on 11 January 2022 and will apply from 12 January 2025.

In the preparatory phase for the implementation of the HTAR (January 2022 – January 2025), this webpage aims at informing national authorities, health technology developers and stakeholders about the development of implementing legislation in accordance with the powers conferred to the Commission by the co-legislators.

In the implementation phase of the HTAR (beyond January 2025, when joint HTA work will start), this webpage will include all the information required by Article 30.3 of the HTAR.

---

- [Factsheet on implementation of the Regulation](#)